Tumor vasculature‐targeted delivery of tumor necrosis factor‐α*
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recently, considerable efforts have been directed toward antivascular therapy as a new modality to treat human cancers. However, targeting a therapeutic gene of interest to the tumor vasculature with minimal toxicity to other tissues remains the objective of antivascular gene therapy. Tumor necrosis factor‐α (TNF‐α) is a potent antivascular agent but has limited clinical utility because of significant systemic toxicity. At the maximum tolerated doses of systemic TNF‐α, there is no meaningful antitumor activity. Hence, the objective of this study was to deliver TNF‐α targeted to tumor vasculature by systemic delivery to examine its antitumor activity. METHODS: A hybrid adeno‐associated virus phage vector (AAVP) was used that targets tumor endothelium to express TNF‐α (AAVP‐TNF‐α). The activity of AAVP‐TNF‐α was analyzed in various in vitro and in vivo settings using a human melanoma tumor model. RESULTS: In vitro, AAVP‐TNF‐α infection of human melanoma cells resulted in high levels of TNF‐α expression. Systemic administration of targeted AAVP‐TNF‐α to melanoma xenografts in mice produced the specific delivery of virus to tumor vasculature. In contrast, the nontargeted vector did not target to tumor vasculature. Targeted AAVP delivery resulted in expression of TNF‐α, induction of apoptosis in tumor vessels, and significant inhibition of tumor growth. No systemic toxicity to normal organs was observed. CONCLUSIONS: Targeted AAVP vectors can be used to deliver TNF‐α specifically to tumor vasculature, potentially reducing its systemic toxicity. Because TNF‐α is a promising antivascular agent that currently is limited by its toxicity, the current results suggest the potential for clinical translation of this strategy. Cancer 2009. Published 2008 by the American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Cited by
Frontiers in cancer nanomedicine: directing mass transport through biological barriers
Ferrari, M. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2009.12.007 · Cited by 255
Bacteriophage-Mediated Cancer Gene Therapy
Petrov, G., Dymova, M., & Richter, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214245 · Cited by 38
UVB-stimulated TNFα release from human melanocyte and melanoma cells is mediated by p38 MAPK
Muthusamy, V., & Piva, T. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140817029 · Cited by 11
(2024) · doi:10.1016/j.omton.2024.200805 · Cited by 8
Self-citation
Metadata
- Authors
- Tandle, A., Hanna, E., Lorang, D., Hajitou, A., Moya, C. A., Pasqualini, R., Arap, W., Adem, A., Starker, E., Hewitt, S., & Libutti, S. K.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-12-29
- Volume
- 115
- Issue
- 1
- Pages
- 128-139
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1979838211
- Cited by
- 83
- References
- 1
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor vasculature‐targeted delivery of tumor necrosis factor‐α*. https://app.cochat.ai/papers/10.1002/cncr.24001
- The paper
- Tandle, A., Hanna, E., Lorang, D., Hajitou, A., Moya, C. A., Pasqualini, R., Arap, W., Adem, A., Starker, E., Hewitt, S., & Libutti, S. K. (2009). Tumor vasculature‐targeted delivery of tumor necrosis factor‐α*. Cancer. https://doi.org/10.1002/cncr.24001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.